These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32713127)

  • 21. The Potential Role of Basophils in Urticaria.
    Takimoto-Ito R; Ma N; Kishimoto I; Kabashima K; Kambe N
    Front Immunol; 2022; 13():883692. PubMed ID: 35663949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cutaneous manifestations in patients with COVID-19 with significant attention to urticaria].
    Sánchez-Borges M; González-Díaz SN; Ortega-Martell JA; Rojo-Gutiérrez MI; Ansotegui-Zubeldia IJ
    Rev Alerg Mex; 2021; 68(2):112-116. PubMed ID: 34525782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiology of urticaria.
    Hennino A; Bérard F; Guillot I; Saad N; Rozières A; Nicolas JF
    Clin Rev Allergy Immunol; 2006 Feb; 30(1):3-11. PubMed ID: 16461989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature.
    Tonacci A; Billeci L; Pioggia G; Navarra M; Gangemi S
    Pharmacotherapy; 2017 Apr; 37(4):464-480. PubMed ID: 28226418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe urticarial rash as the initial symptom of COVID-19 infection.
    Pagali S; Parikh RS
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33766974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of IgE in autoimmunity.
    Sanjuan MA; Sagar D; Kolbeck R
    J Allergy Clin Immunol; 2016 Jun; 137(6):1651-1661. PubMed ID: 27264000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).
    Carrascosa JM; Morillas V; Bielsa I; Munera-Campos M
    Actas Dermosifiliogr (Engl Ed); 2020 Nov; 111(9):734-742. PubMed ID: 32882184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification, Mechanism, and Treatment of Skin Lesions in COVID-19: A Review.
    Fernández-Lázaro D; Garrosa M
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmacytoid dendritic cells during COVID-19: Ally or adversary?
    Van der Sluis RM; Holm CK; Jakobsen MR
    Cell Rep; 2022 Jul; 40(4):111148. PubMed ID: 35858624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.
    Serrano-Candelas E; Martínez-Aranguren R; Vega O; Gastaminza G; Bartra J; Audicana MT; Núñez-Córdoba JM; Algorta J; Valero A; Martin M; Ferrer M
    Sci Rep; 2017 Aug; 7(1):8985. PubMed ID: 28827590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mast cells: Therapeutic targets for COVID-19 and beyond.
    Lam HY; Tergaonkar V; Kumar AP; Ahn KS
    IUBMB Life; 2021 Nov; 73(11):1278-1292. PubMed ID: 34467628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urticaria and Angioedema: an Update on Classification and Pathogenesis.
    Radonjic-Hoesli S; Hofmeier KS; Micaletto S; Schmid-Grendelmeier P; Bircher A; Simon D
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):88-101. PubMed ID: 28748365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
    Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
    Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omalizumab inhibits acceleration of FcεRI-mediated responsiveness of immature human mast cells by immunoglobulin E.
    Okayama Y; Kashiwakura J; Sasaki-Sakamoto T; Matsumoto K; Hashimoto N; Ohmori K; Kawakami T; Saito H; Ra C
    Ann Allergy Asthma Immunol; 2012 Mar; 108(3):188-94. PubMed ID: 22374203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.
    Moñino-Romero S; Erkert L; Schmidthaler K; Diesner SC; Sallis BF; Pennington L; Jardetzky T; Oettgen HC; Bohle B; Fiebiger E; Szépfalusi Z
    Allergy; 2019 Feb; 74(2):236-245. PubMed ID: 30030936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.